Protect the sacred space of leisure from being contaminated by work
Interested in more careers-related content? Check out our new weekly Work Life newsletter. Sent every Monday afternoon.
Gloria Mark, a leading researcher on attention and distraction and University of California informatics professor, warns us to beware of leisure contamination: The tendency while taking a break to still be wrestling with work and family responsibilities. It's a mental spillover of stress into those rare moments that are meant to be restful.
'Psychological detachment – fully detaching from stressors during leisure time – is crucial for recovery from stress. But achieving it in our always-connected, always-on, busy culture is getting harder and harder to do,' she writes on her Substack blog.
Most of us believe leisure time has been shrinking. But she says the quantity has remained constant over the past 20 years; what has changed is how we spend it, with an extra two hours spent watching screens – smartphones, other personal devices and television. Despite leisure time remaining consistent, however, stress levels have risen sharply.
'Even when we set aside time to relax, we often don't take full advantage of it, allowing our minds to remain tethered to screens, work or other responsibilities. It's like a faucet that never fully turns off – a steady drip, drip, drip of stress that contaminates our leisure time. All kinds of external pressures like demanding jobs, financial concerns, social expectations and disturbing world events in the news intrude on our rest, preventing the mental and emotional recovery that leisure time is meant to provide,' she says.
To reduce leisure contamination, she advises us to consciously separate work from leisure. That means no emails or messages and no thinking about your next report during downtime. 'Leisure must be protected as a distinct and sacred space,' she says.
Approach leisure time with intention. Consider it a valuable resource, not just filler time. Choose activities that rejuvenate you. 'Despite having the time to unwind, many of us squander it – not by choice, but because of ingrained habits and external intrusions,' she writes.
For many people, the biggest block of continuous leisure time is our vacations. It can be hard to avoid contamination and in some cases nearly impossible. Maybe you're a sole entrepreneur or a lawyer prepping for a big trial or someone else with an important, upcoming critical deadline. It may be even more important in those situations to ensure refreshing time away, in essence avoiding contamination in the part of the vacation that must be contaminated.
Time management coach Elizabeth Grace Saunders says that delicate balance starts with telling people you are away – on vacation. Your instinct may be the opposite but an out-of-office responder reduces your worry about what others are thinking when you don't react quickly to them.
You also want to avoid compulsively checking your messages to ensure no emergency is occurring. 'For any days where you're not working the full day, have a designated person who can field most items and contact you if a true emergency comes up. Prep them on exactly when you want to be contacted,' she writes in Harvard Business Review.
Don't leave your work hours undefined on the break. To the extent that you can, determine your work start and stop times in advance for your own sake and those of people travelling with you.
'I recommend frontloading any longer stretches of work while you have momentum from having just left the office, then tapering down so you feel like you can get more and more relaxed throughout your travels,' she says.
If you need to commit to fixed meeting times, arrange them for the start of the day because you will have less control of what happens as the day unfolds and delays occur or plans change with the weather or impulse.
Finally, resist opening messages on non-urgent, non-critical items. 'To have space in your schedule to relax, you need to do less than you would if you were in the office. If you're travelling but still doing some work, it's tempting to answer a random question, help someone out or otherwise participate in non-urgent work items 'real quick.' But if you want to feel like you took some real time off, you can't engage in everything you typically would in the office,' she warns.
Quick Hits
Harvey Schachter is a Kingston-based writer specializing in management issues. He, along with Sheelagh Whittaker, former CEO of both EDS Canada and Cancom, are the authors of When Harvey Didn't Meet Sheelagh: Emails on Leadership.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
39 minutes ago
- CTV News
Despite Kennedy's claims, vaccines have been tested in placebo-controlled studies
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly claimed that most vaccines recommended for children in the U.S. have not been tested against inert placebos. (Demetrius Freeman/Thevia CNN Newsource) U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly claimed in public statements that most vaccines recommended for children in the U.S. have not been tested against placebos, and particularly inert placebos such as saline solution or water. 'The only vaccine that has been tested in a full-blown placebo trial against an inert placebo was the Covid vaccine,' Kennedy said May 14 in testimony before the U.S. Senate's Health, Labor, Education and Pensions Committee. 'The other 76 shots that children in this country received between birth and 18 years old, none of them have been safety tested in prelicensing studies against the placebo, which means we don't understand the risk profile for those products, and that's something I intend to remedy,' he told Sen. Chris Murphy, D-Connecticut. In 2023, Kennedy told Fox News host Jesse Watters: 'Vaccines are exempt from prelicensing placebo-controlled trials, so that there's no way that anybody can tell the risk profile of those products or even the relative benefits of those products before they're mandated. And we should have that kind of testing.' HHS is acting on Kennedy's claims, too. The department recently announced it will require all new vaccines be tested in placebo-controlled trials before they're licensed for use, a change it called 'a radical departure from past practices.' These claims made Dr. Jake Scott's ears perk up. Scott, an infectious disease specialist at Stanford University, knew that the assertions couldn't be true, and now he says he has the proof. Scott launched a project in April to round up every randomized and placebo-controlled clinical trial of vaccines in the medical literature, including studies run in other countries, since some vaccines used in the U.S. are tested overseas. It took five weeks to arrive at a number: There have been 258 randomized, controlled clinical trials of vaccines, according to Scott and a team of volunteers who scoured databases of medical literature. More than half of those studies — 153 — tested vaccines against placebos, and 127 of those studies used inert placebos. A randomized, controlled trial may use another vaccine. For their dataset, Scott said they considered a trial placebo-controlled only if the placebo didn't contain an antigen — the active vaccine ingredient. Based on Scott's research, at least nine of the 16 vaccines that are routinely recommended by the U.S. Centers for Disease Control and Prevention for children have been tested against inert placebos, while several more have been tested against active controls, such as another type of vaccine. In scientific research, randomized, placebo-controlled clinical trials are considered to generate the highest-quality evidence. That's because they split their study participants into equal groups; some get the study intervention or treatment, while others get a placebo or dummy remedy. Placebos are often carefully designed to look, taste or even smell like the intervention that's being tested. The idea is to keep both the participants and the researchers themselves in the dark about who's getting the real thing until the end of the study, when the results are analyzed and reported, to prevent any potential bias. HHS did not respond to CNN's request for comment on the new project's findings or clarification on Kennedy's statements. Crowdsourcing vaccine research On April 22, Scott posted a link to a shared Google spreadsheet online, along with some ground rules about which trials could and couldn't be included. The studies had to be in humans; no animal studies or lab-only investigations allowed. The researchers also used a particular set of search terms, with no limits on dates, languages or pathogens. The team then read each study that was found to make sure it met the specified criteria for inclusion in the review. 'It took off,' Scott said. He estimates that the project had five or six core contributors, but they had help from around the world. Together, they scoured PubMed, the database of medical research maintained by the National Library of Medicine, as well as reference lists from Cochrane, the World Health Organization and the CDC. Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto, said he was blown away when he saw the final list of studies, which included about 2.5 million participants in total. 'The body of evidence for many of the vaccines that we use is very impressive, and the data is robust,' said Bogoch, who didn't contribute to the project. 'This type of work is extremely important in era of unprecedented vaccine hesitancy.' A 'demonstrably false' claim Scott said the research proves that Kennedy's statements are 'demonstrably false.' To understand why, it's useful to break down the parts of Kennedy's argument, which he has repeated in different iterations for years. Kennedy has shifted the goalposts, but there are a few things he has said would make a clinical trial meet his requirements: First, an inert placebo, meaning a placebo control that didn't have any biological effects on the body, like water or saline solution. Kennedy has said that without comparison to an inert placebo, the true side effects of vaccines can't be fully understood. He also uses the term 'prelicensing,' meaning the research is conducted before the U.S. Food and Drug Administration has approved the vaccines. The FDA sometimes accepts enough evidence to approve a vaccine but then will require more safety studies and monitoring after approval. Kennedy and other critics argue that more safety testing should be done before the vaccines are approved in the first place. In some instances, Kennedy has also said that these studies should be large, including many participants, and long-running. In general, larger studies have greater statistical power to show subtle differences between groups. And the longer a trial follows its participants, the more confident researchers can be in the durability of their results. Although scientists agree that larger and longer clinical trials are the most reliable, these studies are expensive to conduct. They can take years to run, which delays the possibility of getting an effective intervention to people. It can also be difficult to find participants who can stick with the monitoring requirements of a study for longer periods of time. In recent testimony, however, even Kennedy seemed to be softening his stance on this particular stipulation, agreeing that other types of studies can provide solid evidence, too. 'You know that the Cochrane Collaboration in 2016 published a study that showed that the predictive capacity of placebo-controlled trials, which are the gold standard, is actually not any better than good observational trials in retrospective trials. So we can do those kind of studies without subjecting people to an unethical experiment,' Kennedy said during a May 20 Senate budget hearing when asked about the need to test established vaccines in large, lengthy placebo-controlled trials. In his 2021 book, 'The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health,' Kennedy repeats the claim that vaccines for children haven't been tested against inert placebos, saying that he and groups he's affiliated with have explicitly asked to be shown such studies. He cites two letters between the Informed Consent Action Network or ICAN, a group run by his close associate Del Bigtree, and HHS. The letter from ICAN asserts that in contrast to most other FDA-approved medications, 'vaccines are not required to undergo long-term double-blind inert-placebo controlled trials to assess safety. In fact, not a single one of the clinical trials for vaccines given to babies and toddlers had a control group receiving an inert placebo.' The HHS letter refutes this claim: 'Contrary to statements made on page two of your letter, many pediatric vaccines have been investigated in clinical trials that included a placebo.' The letter goes on to say inert placebos are not necessary to understand the safety of a new vaccine, and so they haven't been required. Still, Scott says the evidence is clear: Of the 258 randomized, controlled vaccine studies he and his colleagues found, about half – 127 – included inert placebos. When it comes to vaccines routinely recommended for children, specifically, Scott found that at least nine of the 16 on the CDC's regular schedule have been tested against inert placebos: These are the vaccines against Covid-19; rotavirus; polio; influenza; measles, mumps and rubella; human papillomavirus; varicella, or chickenpox; pneumococcal; and H-flu, or Haemophilus influenzae. One of the largest of these trials was on the polio vaccine. The placebo-controlled part of the study included more than 400,000 grade-schoolers. Half got the inactivated polio vaccine created by Dr. Jonas Salk, and the other half were given injections of an inert placebo, which was saline solution. The trial was conducted in 1954, and the results were announced in April 1955. So great was the urgency to get the vaccine to kids that the FDA licensed it the same day. 'It's frankly astounding that someone who made such easily disprovable claims is now heading HHS and continues to promote similar misinformation,' Scott said of Kennedy in an email to CNN. 'We compiled this evidence specifically to counter these false narratives with hard data.' Scott says he and his colleagues hope to have their project published in peer-reviewed medical journal soon. For now, it's available in a publicly posted spreadsheet. Vaccines In scientific research, randomized, placebo-controlled clinical trials are considered to generate the highest-quality evidence. (via CNN Newsource_ Active controls vs. inert placebos Vaccine trials that don't use inert placebos will sometimes use what are known as active controls. These comparison shots have some biological effect but don't interfere with scientists' ability to interpret the results of their study. Active controls are used for a variety of reasons. In some parts of the world, for example, where it might be difficult to recruit participants, researchers might give the control group an unrelated vaccine to make sure they're getting some benefit by enrolling in the study. One study published last year in the Lancet, testing a vaccine against malaria, gave participants in the control group a vaccine against rabies instead. Rabies vaccines don't protect against malaria, so they wouldn't interfere with researchers' ability to tell whether the malaria shot actually worked. Other types of controls in the studies in Scott's project included shots that contained only an adjuvant, an ingredient that's added to vaccines to trigger a stronger immune response. Dr. Greg Poland, who studies how adults and children respond to vaccines at the Mayo Clinic, said it would be a mistake to assume that active controls can't be valid and rigorous ways to test vaccines. Adjuvants, such as aluminum, are often the reason people get soreness around an injection site. Giving just the adjuvant can guard against even psychological bias in control participants who might guess that they didn't get a real vaccine if they didn't feel anything after their shots. It also allows researchers to isolate the benefits and side effects of the vaccine, since everyone got the adjuvant. 'You're literally saying, 'OK, we're testing a vaccine that has ingredient A plus B against a non-vaccine placebo that has ingredient B.' So the only thing different between the two of them is the actual vaccine,' Poland said. An active comparator might also be used rather than an inert placebo because of ethics. When there's already a vaccine that's considered to be safe and effective against an infection, it's considered unethical to deny study participants the chance to get it. In that case, companies that want to test a new and improved version of a vaccine against an older one would normally have to offer participants in their control group the older vaccine. Many modern vaccines have been compared against older versions of the same vaccine. Flu vaccines are a good example, Poland says. If you were testing an improved type of flu vaccine, chances are that the board that oversees your clinical trial wouldn't approve a study that used an inert placebo – especially if you were testing it in a vulnerable group, like people over 65, for whom an infection is more likely to be dangerous. 'It's unethical because the recommendation is that everyone, each flu season, receive an influenza vaccine. So it'd be unethical to enroll people in a study where they may just get placebo and not get any benefit of protection,' Poland said. Poland said he's been puzzled by Kennedy's statements, too. He's concerned that they are getting traction with the public now that Kennedy is the head of the nation's health agencies. 'This notion that there are no placebo-controlled vaccine trials is patently false, but it's a really interesting phenomenon that I have a hard time understanding,' he said. Article by Brenda Goodman.
Globe and Mail
an hour ago
- Globe and Mail
Stocks Finish Sharply Higher on a Resilient US Labor Market
The S&P 500 Index ($SPX) (SPY) Friday closed up +1.03%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +1.05%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.99%. June E-mini S&P futures (ESM25) are up +1.04%, and June E-mini Nasdaq futures (NQM25) are up +0.99%. Stock indexes rallied sharply on Friday, with the S&P 500 posting a 3-1/2 month high and the Dow Jones Industrials posting a 3-month high. Stocks settled sharply higher after Friday's better-than-expected US May employment report alleviated concerns of an economic slowdown. Also, the resumption of US-China trade talks gave stocks a boost after President Trump said that US and Chinese negotiators will resume trade talks on Monday in London. Tesla rose more than +3% Friday after plunging -14% on Thursday when President Trump proposed ending government contracts and subsidies for Elon Musk's companies. Shares of Tesla recovered Friday when Musk, who triggered the public feud by criticizing President Trump's tax bill, signaled he's keen to dial down the hostility. US May nonfarm payrolls rose +139,000, stronger than expectations of +126,000, although Apr nonfarm payrolls were revised lower to +147,000 from the previously reported +177,000. The May unemployment rate remained unchanged at 4.2%, right on expectations. US May average hourly earnings rose +0.4% m/m and +3.9% y/y, stronger than expectations of +0.3% m/m and +3.7% y/y. US Apr consumer credit rose +$17.873 billion to a 4-month high, better than expectations of +$10.000 billion. Fed comments on Friday were mixed for stocks and bonds. On the bearish side, Cleveland Fed President Hammack said she'd rather wait for further clarity on the economic impact of a variety of policy changes before adjusting interest rates, and now "is not a good time to be preemptive." Conversely, Philadelphia Fed President Harker favors the Fed waiting before cutting rates and said, "I could see in the second half of the year, if things resolve themselves, and we start to see more clarity, and we continue to see inflation coming down to 2%, I could definitely see a rate cut in the offing." The markets are discounting the chances at 0% for a -25 bp rate cut at the next FOMC meeting on June 17-18. Overseas stock markets on Friday settled higher. The Euro Stoxx 50 closed up +0.36%. China's Shanghai Composite rose to a 2-week high and closed up +0.04%. Japan's Nikkei Stock 225 closed up +0.50%. Interest Rates September 10-year T-notes (ZNU2 5) Friday closed down -28.5 ticks. The 10-year T-note yield rose +11.9 bp to 4.510%. Sep T-notes on Friday gave up an early advance and fell to a 1-week low, and the 10-year T-note yield rose to a 1-week high of 4.512%. T-notes retreated Friday on the hawkish US May payroll report that showed a larger-than-expected increase in nonfarm payrolls and a larger-than-expected increase in average hourly earnings. T-notes added to their losses Friday on hawkish comments from Cleveland Fed President Hammack, who said she'd rather wait before adjusting interest rates. T-notes on Friday initially posted modest gains on carryover strength from a rally in 10-year German bunds. European government bond yields on Friday were mixed. The 10-year German bund yield fell -0.7 bp to 2.576%. The 10-year UK gilt yield rose +2.8 bp to 4.644%. Eurozone Q1 GDP was revised higher to +0.6% q/q and +1.5% y/, stronger than expectations of +0.4% q/q and +1.2% y/y. Eurozone Apr retail sales rose +0.1% m/m, weaker than expectations of +0.2% m/m. German Apr industrial production fell -1.4% m/m, weaker than expectations of -1.0% m/m. ECB Governing Council member Stournaras said, "The bar for another ECB rate cut is high, in July and beyond," and the ECB should pause its interest rate cuts to give officials a chance to assess recent shocks, particularly from trade. Swaps are discounting the chances at 27% for a -25 bp rate cut by the ECB at the July 24 policy meeting. US Stock Movers Chip makers moved higher on Friday to boost the broader market. Marvell Technology (MRVL) closed up more than +4%. Also, Analog Devices (ADI), Micron Technology (MU), and ARM Holdings Plc (ARM) closed up more than +2%. In addition, Applied Materials (AMAT), Lam Research (LRCX), KLA Corp (KLAC), Microchip Technology (MCHP), ON Semiconductor (ON), NXP Semiconductors NV (NXPI), Texas Instruments (TXN), and Qualcomm (QCOM) closed up more than +1%. Strength in the Magnificent Seven stocks was a positive factor for the overall market. Alphabet (GOOGL) closed up more than +3%, and (AMZN) closed up more than +2%. Also, Apple (AAPL), Nvidia (NVDA), and Meta Platforms (META) closed up more than +1%. In addition, Microsoft (MSFT) closed up +0.58%. Energy stocks and energy service providers moved higher on Friday after the price of WTI crude rose more than +1% to a 1-1/2 month high. APA Corp (APA) closed up more than +3%. Also, Chevron (CVX), Exxon Mobil (XOM), Haliburton (HAL), Baker Hughes (BKR), ConocoPhillips (COP), Devon Energy (DVN), Diamondback Energy (FANG), and Schlumberger (SLB) closed up more than +2%. Tesla (TSLA) closed up more than +3% after CEO Musk signaled he would cool tensions with President Trump following Thursday's dispute that sank Tesla stock by more than -14% when Musk called for Trump's impeachment and President Trump proposed ending government contracts and subsidies for Elon Musk's companies. QXO Inc (QXO) closed up more than +13% after Wolfe Research initiated coverage on the stock with a recommendation of outperform and a price target of $44. Quanex Building Products (NX) closed up more than +10% after reporting Q2 net sales of $452.5 million, stronger than the consensus of $439.3 million. Sarepta Therapeutics (SRPT) closed up more than +9% after Scotiabank upgraded the stock to sector outperform from sector perform with a price target of $80. Lululemon Athletica (LULU) closed down more than -19% to lead losers in the S&P 500 and Nasdaq 100 after cutting its full-year EPS estimate to $14.58-$14.78 from a previous estimate of $14.95-$15.15. Docusign (DOCU) closed down more than -18% after reporting Q1 billings of $739.6 million, below the consensus of $746.4 billion, and cutting its full-year billings forecast to $3.29 billion-$3.34 billion from a previous forecast of $3.30 billion-$3.35 billion, weaker than the consensus of $3.32 billion. Vera Therapeutics (VERA) closed down more than -25% after Japanese rival Otsuka gave results from a trial of its experimental therapy for kidney disease that was better than Vera's data. ServiceTitan (TTAN) closed down more than -6% after reporting a Q1 loss per share of -51 cents, a wider loss than the consensus of -37 cents. Mosaic (MOS) closed down more than -4% after cutting its Q2 phosphates sales volume forecast to 1.5 million to 1.6 million tons from a previous forecast of 1.7 million to 1.9 million tons, well below the consensus of 1.84 million tons. Broadcom (AVGO) closed down more than -4% despite reporting better-than-expected Q2 earnings after analysts' said its future forecast isn't seen as strong enough to extend the stock's recent strength. MercadoLibre (MELI) closed down more than -3% after Citigroup opened a 30-day downside catalyst watch on the stock, citing the potential risk the company is taking to improve pricing and preserve market share. Earnings Reports (6/9/2025) Borr Drilling Ltd (BORR), Calavo Growers Inc (CVGW), Casey's General Stores Inc (CASY), Gencor Industries Inc (GENC), Graham Corp (GHM), Hooker Furnishings Corp (HOFT), Limoneira Co (LMNR), NexPoint Diversified Real Estate Trust (NXDT).
Globe and Mail
an hour ago
- Globe and Mail
U.S. Wireless Speakers Market Growth Potential: $12.12 Billion Opportunity by 2030 – Exclusive Research Report by Arizton
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030. According to Arizton's latest research report, the U.S. wireless speakers market is growing at a CAGR of 12.01% during 2024-2030. Report Scope: Market Size – Value (2030): $12.12 Billion Market Size – Value (2024): $6.14 Billion CAGR - Value (2024-2030): 12.01% Market Size – Volume (2030): 178 Million Units Historic Year: 2021-2023 Base Year: 2024 Forecast Year: 2025-2030 Market Segmentation: Connectivity, Design, Portability, Age Group, End-User, and Distribution Channel The US wireless speakers market is growing significantly due to the popularity of portable speakers, increased demand for customization and personalization, popularity of smart speakers, sustainability and eco-friendly designs, increased online music streaming, demand for smart home integration, increased outdoor activities and adventures, and immersive audio experience. The demand for modern wireless speakers with stylish and sleek designs is growing trendy from commercial spaces, as they complement commercial spaces. The demand for voice-enabled speakers is on the rise, as they can recognize voice and offer hands-free control over manual speakers. The popularity of devices, such as Amazon Echo and Google Home is on the rise across smart homes in the US. Key Developments In September 2021, Bose Corporation launched the Bose Smart Soundbar 900 in the US. The Smart Soundbar 900 has Wi-Fi, Bluetooth, Chromecast built-in, Apple Airplay 2, and Spotify Connect compatibility. The Soundbar 900 is an all-in-one device that replaces the Bose Smart Soundbar 700. In 2024, Apple-owned audio brand, Beats launched Beats Pill. The Beats Pill speaker's upgraded acoustic architecture delivers powerful, room-filling sound, greater bass, and improved tonality across the audio spectrum. The Beats Pill's streamlined design features a 20-degree upward tilt to help deliver sound waves towards your head, away from objects that might obstruct them. Surge in Music Streaming Drives Rapid Growth in U.S. Wireless Speakers Market The US wireless speakers market is experiencing remarkable growth, primarily fueled by the rise in online music streaming. With services like YouTube Music, Apple Music, and Spotify offering millions of songs, podcasts, and personalized playlists, consumers are turning to wireless speakers for enhanced audio experience. The increasing demand for high-quality, portable audio solutions is shaping the future of the market. Wireless speakers offer a seamless and convenient solution for music lovers, enabling them to stream content directly without the need for physical connections. As audio streaming services continue to evolve, offering high-resolution sound, consumers are seeking devices that can deliver superior audio performance. This demand is being met by advances in wireless technology that enable better sound quality and a more immersive listening experience. The portability of wireless speakers makes them ideal for on-the-go listening, whether during outdoor activities, while traveling, or in the comfort of one's home. The convenience of multi-room audio capabilities further enhances the appeal, allowing users to enjoy their music wherever they are. The music streaming industry continues to thrive, with the Recording Industry Association of America (RIAA) reporting an 8% increase in recorded music revenue in 2023, demonstrating a continued growth trend. As streaming platforms proliferate, so does the demand for wireless speakers, making it clear that wireless audio solutions are integral to the evolving music consumption landscape. Online Segment Leading the US Wireless Speakers Market Sales The online segment is emerging as the fastest-growing distribution channel in the US wireless speakers market, driven by e-commerce platforms, manufacturer websites, and online marketplaces. Offering competitive pricing, detailed product information, and a wide range of options across different brands and features, online platforms provide consumers with a convenient shopping experience. Retailers are leveraging targeted digital marketing, using demographic data and consumer behavior insights to effectively reach potential customers. Enhanced customer service features such as easy returns, live chat support, and comprehensive product details are further fueling demand. As a result, the online channel is expected to see significant growth in wireless speaker sales during the forecast period. Key Vendors Anker Amazon Apple Bose Corporation LG Logitech Marshall Group AB Samsung Sonos Sony Altec Lansing Alphabet Inc. Audio Pro AB Axess Products Corporation Bang & Olufsen Creative Technology Ltd. DEI Holdings DemerBox Denon DOSS Audio Edifier Elgin USA FUGOO Guangzhou AUSMAN Audio Co., iClever ION Audio Jam Klipsch Group Koninklijke Philips N.V., Lenovo LG Electronics Linn Products Limited Loud Audio, LLC Monster Store MPOW Naim Audio Onkyo Corporation Panasonic RCF Robert Bosch SDI Technologies, Inc. Sennheiser Skullcandy SoundBot SOUNDBOKS Supersonic The House of Marley Tribit VictSing Yamaha Corporation Segmentation & Forecasts Connectivity Bluetooth Wi-Fi By Design Waterproof Non-Waterproof Portability Portable Fixed Age Group Below 44 45 & Above End-User Residential Commercial Distribution Channel Offline Online The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the U.S. wireless speaker market. Request for Free Sample to get a glance of the report now: What Key Findings Will Our Research Analysis Reveal? How big is the U.S. wireless speakers market? Which connectivity segment has the largest share in the U.S. wireless speakers market? Which portability segment provides more business opportunities in the U.S. wireless speakers market? Which age group segment holds the largest share in the U.S. wireless speakers market? Who are the major players in the U.S. wireless speakers market? Why Arizton? 100% Customer Satisfaction 24x7 availability – we are always there when you need us 200+ Fortune 500 Companies trust Arizton's report 80% of our reports are exclusive and first in the industry 100% more data and analysis 1500+ reports published till date Post-Purchase Benefit 1hr of free analyst discussion 10% off on customization About Us: Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
